NCT00658567 - A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis | Biotech Hunter

Enrollment

123

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions

Parkinson's Disease Psychosis

Interventions

DRUG

Pimavanserin tartrate (ACP-103)

10 mg, tablet, once daily by mouth, for six weeks

DRUG

Pimavanserin tartrate (ACP-103)

20 mg, tablet, once daily by mouth, for six weeks

DRUG

Pimavanserin tartrate (ACP-103)

Placebo, tablet, once daily by mouth, for six weeks

Trial Locations (50)

1090

Brussels

1340

Ottignies

6020

Innsbruck

8800

Roeselare

11000

Belgrade

11725

Commack

12208

Albany

15706

Santiago de Compostela

19131

Philadelphia

19141

Philadelphia

20009

Donostia / San Sebastian

27705

Durham

28204

Charlotte

32405

Panama City

33064

Deerfield Beach

34233

Sarasota

43614

Toledo

48035

Clinton

48201

Detroit

48824

East Lansing

58100

Grossetto

65201

Columbia

66013

Chieti Scalo

68131

Omaha

77030

Houston

80113

Englewood

90631

La Habra

92653

Laguna Hills

93003

Ventura

Unknown

Reseda

New Bern

06030

Farmington

02215

Boston

01655

Worcester

05401

Burlington

00163

Roma

00185

Roma

85-096

Bydgoszcz

40-752

Katowice

90-130

Lodz

20-090

Lublin

3000-548

Coimbra

1649-028

Lisbon

4099-001

Porto

08003

Barcelona

08036

Barcelona

08195

Barcelona

SE-551 85

Jönköping

SE-581 85

Linköping

SE-112 45

Stockholm